MEDIPOST obtained a patent in China for its pharmaceutical composition that can be used for preventing and treating cranial nerve diseases.

The title of this patent is ‘Composition for the diagnosis, prevention or treatment of disease related to cells expressing IL-8 or GRO-alpha, comprising UCB-MSCs’.

This patented technology was developed using stem cells’ tropism or the ability to search and track lesions in our body. This technology can be used for the prevention, treatment and diagnosis of brain tumors and cranial nerve diseases including Alzheimer’s disease.

Using stem cells as a vehicle when treating cranial nerve disease can enhance the efficacy of medications and make administration of medications more easy.

MEDIPOST already has a similar patent in Korea, US, Canada, UK, France, Germany, Italy, Spain, Switzerland, Mexico, Japan and China.